Marvin A Sackner, M.D., Chief Executive Officer and Chairman, Board of Directors, Non-Invasive Monitoring Systems, Inc. (NIMS) (OTCBB:NIMU), announced that Drs. Matsumoto, Fujita and associates from the Shiga University of Medical Sciences, Kyoto University Graduate School of Medicine, Okamura Memorial Hospital, Japan published a paper entitled, “Whole-body periodic acceleration enhances brachial endothelial function” in the January 2008 issue of Circulation Journal. Whole-body periodic acceleration (WBPA) is accomplished by using a non-invasive, bed-like platform that moves a supine subject repetitively head to foot about 140 times a minute simulating brisk exercise. This device, called the AT-101, is a first generation model of acceleration therapeutic devices manufactured by NIMS.
In this paper, Matsumoto and associates pointed out that “Habitual physical activity may reduce the risk of cardiovascular disease, but the prevalence of physical inactivity is increasing. This life-style change is of interest because physical inactivity has been proposed as an independent cardiovascular risk factor. Studies of endurance exercise training support the notion that it is effective for preventing cardiovascular events.”
Brachial artery function, which is an independent predictor of cardiovascular disease events, can be assessed with a standard technique. Matsumoto and associates made such measurements in 26 adult unfit volunteers who did not regularly exercise. All were assigned to 4 weeks of sedentary activity and 4 weeks of WBPA (5 sessions of 45 minutes each per week) in a statistically valid design. WBPA improved brachial arterial function but sedentary activity did not change it. Matsumoto and associates concluded that WBPA “might substitute or complement active exercise in patients whose medical condition limits physical activity.”
Dr. Sackner noted that “others have shown that a vigorous exercise training program in young men with average fitness improved brachial artery function. Matsumoto’s study demonstrates that such improvement in unfit individuals can also be obtained with WBPA and therefore serve as an aid to achieve wellness. A second generation, improved WBPA device, called Exer-Rest™, has been designed for utilization in the home, clinic or hospital.” Dr. Sackner added that “Exer-Rest™ might also be considered as an alternative or complementary means to exercise for the management of cardiovascular diseases.”
A clinical trial is currently underway to support the intended use of Exer-Rest™ for temporary relief of musculoskeletal pain associated with osteoarthritis of the lower extremities (hips and knees) in order to meet FDA approval for its marketing in the United States. The Company will export Exer-Rest™ in February 2008 to countries that recognize the CE mark.
Further information on the Company can be obtained on NIMS’ website at www.nims-us.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission